News Veru to Report Fiscal 2021 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 2nd MIAMI , Nov. 18, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that it will report financial results for its fiscal 2021 fourth quarter and full November 18th, 2021 Veru Ranked as one of the Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500 -- Veru is a Late-Stage Clinical Development Biopharmaceutical Company Developing Drugs for the Treatment of Breast Cancer, Prostate Cancer, and COVID-19, Large Premium Global Markets– -- 212% Revenue Growth Over Last Three Fiscal Years from Sexual Health Division-- --Sexual Health Division Based November 18th, 2021 Veru to Participate in Fireside Chat at the Jefferies London Healthcare Conference on November 16-18, 2021 MIAMI , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that the Company will participate in a fireside chat at the Jefferies London November 8th, 2021 Veru Enrolls First Patient in International Phase 3 ARTEST Clinical Trial of Enobosarm in Metastatic Breast Cancer -- Enobosarm is a novel targeted hormone drug to be evaluated in the 3 rd line treatment of androgen receptor positive metastatic breast cancer -- -- A companion diagnostic test will be developed, validated, and used to select patients who are most likely to respond to enobosarm treatment -- -- The October 13th, 2021 Veru Announces Positive Updated Data from Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress MIAMI , Sept. 20, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that updated clinical data from the positive Phase 1b/2 study of sabizabulin September 20th, 2021 1 2 ··· 51 52 53 Next Search for: Investors Press Releases Stock Information Financial Information Investor Presentations Corporate Governance Stock Chart VERU (NASDAQ CM) Last Trade: 7.77 Date: November 26, 2021 1:00 pm Change: -0.12 MIAMI | LONDON | MALAYSIA © 2021 Veru Inc. | All Rights Reserved | Accreditation and Certificates | Privacy Policy | Anti-Trafficking Policy | Terms of Use | Contact Us Website Design by Get Sharp, Inc.